A. Rivero

发表

HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy

J. Torre-Cisneros, M. Frias, D. Rodriguez-Cano, 2016, The Pharmacogenomics Journal.

Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.

A. Rivero, J. Garau, M. Twynholm, 2003, The Journal of antimicrobial chemotherapy.

Early Hemoglobin kinetics in response to ribavirin: Safety lesson learned from Hepatitis C to CoVID-19 therapy

M. Frias, Á. Camacho, A. Rivero‐Juárez, 2020, medRxiv.

Liver Stiffness as a Predictor of Esophageal Varices Requiring Therapy in HIV/Hepatitis C Virus-Coinfected Patients With Cirrhosis

J. Macías, J. Pineda, Á. Camacho, 2009, Journal of acquired immune deficiency syndromes.

Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes.

M. Crespo, J. Pineda, A. Rivero, 2015, Antiviral research.

Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

P. Soler-Palacín, Á. Holguín, J. Losa, 2020, Scientific Reports.

The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities

M. Frias, Á. Camacho, A. Rivero‐Juárez, 2020 .

The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype

J. Torre-Cisneros, Á. Camacho, A. Rivero‐Juárez, 2013, AIDS.

50 BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN FOR THE TREATMENT OF HCV/HIV CO-INFECTED PATIENTS: END OF TREATMENT (WEEK 48) INTERIM RESULTS

C. Cooper, J. Mallolas, S. Pol, 2012 .

Selective reactivation of human herpesvirus 6 variant a occurs in critically ill immunocompetent hosts.

Thomas F. Smith, T. F. Smith, W. Kremers, 2002, The Journal of infectious diseases.

Risk factors for pulmonary Aspergillus terreus infection in patients with positive culture for filamentous fungi.

J. Torre-Cisneros, A. Rivero, M. J. Linares, 2007, Chest.

Efficacy of Low-Dose Boosted Saquinavir Once Daily Plus Nucleoside Reverse Transcriptase Inhibitors in Pregnant HIV-1-Infected Women With a Therapeutic Drug Monitoring Strategy

Á. Camacho, A. Rivero, P. Viciana, 2007, Therapeutic drug monitoring.

Indirect effects of cytomegalovirus infection in solid organ transplant recipients.

R. Solana, J. Torre-Cisneros, A. Rivero, 2008, Enfermedades infecciosas y microbiologia clinica.

Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients

C. Cooper, M. Laguno, S. Pol, 2012 .

Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients.

V. de Lédinghen, C. Quereda, J. Macías, 2008, Journal of hepatology.

Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study

A. Lazzarin, D. Dieterich, J. Rockstroh, 2017, Hepatology International.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

J. Mallolas, S. Pol, A. Howe, 2013, The Lancet. Infectious diseases.

Clinical progression of hepatitis C virus–related chronic liver disease in human immunodeficiency virus–infected patients undergoing highly active antiretroviral therapy

J. Rodríguez-Baño, J. Macías, J. Pineda, 2007, Hepatology.

Present-day treatment of tuberculosis and latent tuberculosis infection.

A. Rivero‐Juárez, A. Rivero, J. M. Kindelán, 2011, Enfermedades infecciosas y microbiologia clinica.

Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice

J. Macías, J. Pineda, A. Rivero‐Juárez, 2018, HIV clinical trials.

HLA-B, HLA-C and KIR improve the predictive value of IFNL3 for Hepatitis C spontaneous clearance

M. Frias, D. Rodriguez-Cano, B. Manzanares-Martín, 2018, Scientific Reports.

Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C

A. Rivero‐Juárez, A. Rivero, J. Berenguer, 2016, Open forum infectious diseases.

Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas.

E. Cordero, J. Pachón, A. Rivero, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus–coinfected patients with mild fibrosis in the short term

J. Macías, J. Pineda, Á. Camacho, 2015, Hepatology.

Liver Fibrosis, Host Genetic and Hepatitis C Virus Related Parameters as Predictive Factors of Response to Therapy against Hepatitis C Virus in HIV/HCV Coinfected Patients

A. Rivero‐Juárez, A. Rivero, L. López-Cortés, 2014, PloS one.

Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients

M. González-Escribano, J. Pineda, A. Rivero, 2012, PloS one.

Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5.

A. Rivero‐Juárez, A. Rivero, A. Rivero-Juarez, 2016, The Lancet. Infectious diseases.

Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

A. Rivero‐Juárez, A. Rivero, L. López-Cortés, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C

F. Cuenca-López, A. Rivero‐Juárez, A. Rivero, 2017, Expert opinion on drug metabolism & toxicology.

Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.

J. Torre-Cisneros, J. Macías, J. Pineda, 2010, The Journal of antimicrobial chemotherapy.

Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients.

M. Frias, A. Rivero‐Juárez, A. Rivero, 2018, Pharmacogenomics.

Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C

M. Frias, A. Rivero‐Juárez, A. Rivero, 2018, Expert opinion on drug metabolism & toxicology.

Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus

J. Macías, J. Pineda, A. Rivero, 2009, Hepatology.

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.

V. Soriano, J. Macías, J. Pineda, 2013, The Journal of infection.

Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals

L. Real, M. Frias, J. Macías, 2015, AIDS.

The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.

J. Macías, J. Pineda, Á. Camacho, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis

J. Macías, J. Pineda, A. Rivero‐Juárez, 2017, AIDS.

Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection

A. Rivero‐Juárez, A. Rivero, T. Brieva, 2017, Expert opinion on drug metabolism & toxicology.

Simplicity and Efficacy of a Once-Daily Antiretroviral Regimen with Didanosine, Lamivudine, and Efavirenz in Naïve Patients: The VESD Study

J. De La Torre, A. Rivero, L. López-Cortés, 2005, HIV clinical trials.

[Clinical management of community-acquired pneumonia].

E. Cordero, J. Pachón, A. Rivero, 2003, Enfermedades infecciosas y microbiologia clinica.

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.

J. Macías, J. Pineda, Á. Camacho, 2011, The Journal of antimicrobial chemotherapy.

Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.

J. Macías, J. Pineda, Á. Camacho, 2008, The Journal of antimicrobial chemotherapy.

Successful Long-Term Treatment with Linezolid for Disseminated Infection with Multiresistant Nocardia farcinica

J. Torre-Cisneros, Á. Camacho, A. Rivero, 2008, Infection.

Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.

J. Macías, J. Pineda, A. Rivero‐Juárez, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients

J. Pineda, A. Rivero, L. López-Cortés, 2008, AIDS.

Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus–coinfected patients

J. Macías, J. Pineda, A. Rivero, 2012, Hepatology.

Failure of Cetirizine to Prevent Nevirapine-Associated Rash: A Double-Blind Placebo-Controlled Trial for the GESIDA 26/01 Study

J. Miro, J. Blanco, E. Ribera, 2004, Journal of acquired immune deficiency syndromes.

Epidemiology of invasive fungal infection.

J. Torre-Cisneros, A. Rivero, J. J. Castón-Osorio, 2008, International journal of antimicrobial agents.

Mutations in the Progesterone Receptor (PROGINS) May Reduce the Symptoms of Acute Hepatitis E and Protect Against Infection

M. Frias, Á. Camacho, A. Rivero, 2019, Front. Microbiol..

Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients

J. Torre-Cisneros, B. Manzanares-Martín, J. Pineda, 2013, PloS one.

CD8(+)HLA-G(+) regulatory T cells are expanded in HIV-1-infected patients.

J. Lozano, M. Frias, J. Peña, 2009, Viral immunology.

Impact of the PROVAUR stewardship programme on linezolid resistance in a tertiary university hospital: a before-and-after interventional study.

E. Pérez-Nadales, J. Torre-Cisneros, A. Rivero, 2016, The Journal of antimicrobial chemotherapy.

Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus–Infected Patients With Nonalcoholic Fatty Liver Disease

L. Real, J. Macías, J. Pineda, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Different distributions of hepatitis C virus genotypes among HIV‐infected patients with acute and chronic hepatitis C according to interleukin‐28B genotype

J. Nattermann, M. Vogel, J. Rockstroh, 2011, HIV medicine.

A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers

L. Real, V. Soriano, J. Macías, 2014, Liver international : official journal of the International Association for the Study of the Liver.

IFNL4 ss469415590 Variant Shows Similar Performance to rs12979860 as Predictor of Response to Treatment against Hepatitis C Virus Genotype 1 or 4 in Caucasians

L. Real, V. Soriano, J. Macías, 2014, PloS one.

Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection

L. Real, V. Soriano, J. Macías, 2013, AIDS.

A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients.

J. Benito, V. Soriano, J. Macías, 2013, The Journal of antimicrobial chemotherapy.

Differences in Virological Response to Peginterferon-&agr; Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b

J. Benito, V. Soriano, J. Pineda, 2012, Journal of acquired immune deficiency syndromes.

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.

J. Benito, J. Nattermann, J. Rockstroh, 2012, Journal of hepatology.

Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients

J. Macías, J. Pineda, Á. Camacho, 2011, AIDS.

Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.

J. Benito, V. Soriano, J. McHutchison, 2011, The Journal of infectious diseases.

Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse

J. Benito, V. Soriano, J. Pineda, 2011, AIDS.

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

Antonio Martínez, J. Macías, J. Pineda, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Epidemiology and clinical impact of infection in patients awaiting heart transplantation.

J. Torre-Cisneros, A. Rivero, J. Arizón, 2013, International Journal of Infectious Diseases.

Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

C. Gortázar, D. Rodríguez-Lázaro, A. Avellón, 2018, Enfermedades infecciosas y microbiologia clinica.

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy

S. Mauss, S. Scholten, J. Fehr, 2015, PloS one.

CD46 Genetic Variability and HIV-1 Infection Susceptibility

M. Clerici, M. Biasin, S. Lo Caputo, 2021, Cells.

Liver stiffness-based strategies predict absence of variceal bleeding in cirrhotic HCV-infected patients with and without HIV-coinfection after sustained virological response.

L. Real, J. Macías, J. Pineda, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pretransplant Interferon‐γ Secretion by CMV‐Specific CD8+ T Cells Informs the Risk of CMV Replication After Transplantation

R. Solana, A. Rodríguez-Benot, J. Torre-Cisneros, 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Role of Defective Thymic Function in Onset of Ganciclovir-Resistant Cytomegalovirus after Cord Blood Transplantation

R. Solana, J. Torre-Cisneros, A. Rivero, 2012, Clinical and Vaccine Immunology.

THE ROLE OF DEFECTIVE THYMIC FUNCTION IN ONSET OF GANCICLOVIR- 1

R. Solana, A. Rivero, S. Ferrando-Martínez, 2012 .

Age-Dependent Association between Low Frequency of CD27/CD28 Expression on pp65 CD8 (cid:1) T Cells and Cytomegalovirus Replication after Transplantation (cid:1)

R. Solana, A. Rodríguez-Benot, J. Torre-Cisneros, 2009 .

What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis

N. Martin, S. Mehta, J. Macías, 2020, BMC Infectious Diseases.

HIV infection is associated with lower risk of hepatocellular carcinoma after sustained virological response to direct-acting antivirals in hepatitis C infected-patients with advanced fibrosis.

L. Real, J. Macías, J. Pineda, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.

J. Pineda, A. Rivero, L. López-Cortés, 2014, The Lancet. Infectious diseases.

KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy

M. Frias, D. Rodriguez-Cano, A. Gordon, 2016, The Pharmacogenomics Journal.

Influence of the combination of low-density lipoprotein receptor and interleukin 28B genotypes on lipid plasma levels in HIV/hepatitis C-coinfected patients.

J. Torre-Cisneros, J. Pineda, Á. Camacho, 2011, Journal of acquired immune deficiency syndromes.

Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.

J. Zamora, J. Navarro, M. Crespo, 2017, Enfermedades infecciosas y microbiologia clinica.

Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice.

D. Podzamczer, J. Arribas, A. Rivero, 2016, AIDS research and human retroviruses.

Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.

B. Clotet, F. Gayá, A. Curran, 2011, The Journal of antimicrobial chemotherapy.

Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.

J. Torre-Cisneros, J. Macías, J. Pineda, 2013, Enfermedades infecciosas y microbiologia clinica.

Liver Stiffness Using Transient Elastography is Applicable to Canines for Hepatic Disease Models

J. M. Domínguez, J. Torre-Cisneros, A. Rivero, 2012, PloS one.

Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry

J. Macías, J. Pineda, Á. Camacho, 2010, European journal of gastroenterology & hepatology.

Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.

J. Pineda, A. Rivero, J. A. Mira, 2007, The Journal of antimicrobial chemotherapy.

Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients.

C. Tural, M. Laguno, M. Crespo, 2010 .

Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV‐infected patients

J. Macías, Á. Camacho, A. Rivero, 2016, HIV medicine.

Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study.

Miguel Ángel Martínez, D. Podzamczer, C. Vidal, 2020, The Journal of antimicrobial chemotherapy.

[Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy].

A. Rivero, F. Lozano, J. Pasquau, 2003, Enfermedades infecciosas y microbiologia clinica.

Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C

Á. Camacho, A. Rivero, A. Rivero-Juarez, 2015, Expert opinion on drug metabolism & toxicology.

Cervical lipomatosis in HIV‐infected patients: a case–control study

A. Del Arco, A. Rivero, F. Lozano, 2007, HIV medicine.

Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.

J. Macías, J. Pineda, A. Rivero, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Persistence of hepatitis E virus in the liver of non-viremic naturally infected wild boar

M. Frias, Á. Camacho, A. Rivero, 2017, PloS one.

The Common Mosquito (Culex pipiens) Does Not Seem to Be a Competent Vector for Hepatitis E Virus Genotype 3

F. Ruiz-Fons, M. Frias, A. Rivero, 2022, Frontiers in Veterinary Science.

Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV

L. Real, J. Macías, J. Pineda, 2022, Clinical Microbiology and Infection.

Impact of age and cytomegalovirus on CD8+ T-cell compartment remodeling after solid organ transplantation: A one-year follow-up study

R. Solana, A. Rodríguez-Benot, J. Torre-Cisneros, 2017, Experimental Gerontology.

Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics

M. Crespo, A. Rivero, M. Vivancos, 2016, Open forum infectious diseases.

Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.

J. Macías, J. Pineda, A. Rivero, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hepatitis E virus in Spanish donors and the necessity for screening

M. Frias, Á. Camacho, A. Rivero, 2019, Journal of viral hepatitis.

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice – Vie-KinD study

J. Mallolas, M. Laguno, J. Losa, 2019, PloS one.

Detection of simultaneous β‐herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection

Thomas F. Smith, T. F. Smith, W. Kremers, 2003, Clinical transplantation.

Control of Epstein-Barr virus load and lymphoproliferative disease by maintenance of CD8+ T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation.

J. Román, J. Torre-Cisneros, A. Rivero, 2004, The Journal of infectious diseases.

Weight changes after first-line antiretroviral initiation in a cohort of HIV-positive patients in Southern Spain (CAPOTA study)

A. Rivero, C. Hidalgo-Tenorio, Jesús Santos, 2022, International journal of STD & AIDS.

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

D. Podzamczer, E. Ribera, J. Macías, 2021, Open forum infectious diseases.

[Skin lesions and fever in an VIH-infected patient].

A. Rivero, R. Salido, M. García-Lázaro, 2012, Enfermedades infecciosas y microbiologia clinica.

Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.

J. Macías, J. Pineda, A. Rivero, 2011, AIDS patient care and STDs.

Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV‐infected patients

J. Macías, A. Rivero, F. Téllez, 2019, HIV medicine.

Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.

J. Torre-Cisneros, J. Macías, J. Pineda, 2011, The Journal of antimicrobial chemotherapy.

Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.

A. Rivero, L. López-Cortés, F. Lozano, 2008, AIDS research and human retroviruses.

Liver stiffness correlates with Child‐Pugh‐Turcotte and MELD scores in HIV/hepatitis C virus‐coinfected patients with cirrhosis

J. Macías, J. Pineda, A. Rivero, 2012, Liver international : official journal of the International Association for the Study of the Liver.

Antiretroviral Therapy Based on Protease Inhibitors as a Protective Factor against Liver Fibrosis Progression in Patients with Chronic Hepatitis C

J. Macías, J. Pineda, A. Rivero, 2005, Antiviral therapy.

Using machine learning methods to determine a typology of patients with HIV-HCV infection to be treated with antivirals

Pedro Antonio Gutiérrez, David Guijo-Rubio, César Hervás-Martínez, 2020, PloS one.

High Seroprevalence But Low Incidence of HCV Infection in a Cohort of Patients With Sexually Transmitted HIV in Andalusia, Spain

A. Rivero, L. López-Cortés, Jesús Santos, 2009, Journal of the International Association of Physicians in AIDS Care.

Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

J. Gatell, E. Martinez, J. De La Torre, 2018, Enfermedades infecciosas y microbiologia clinica.

Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

J. Gatell, J. De La Torre, M. Crespo, 2017, Enfermedades infecciosas y microbiologia clinica.

Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

D. Podzamczer, B. Clotet, J. Miro, 2017, Enfermedades infecciosas y microbiologia clinica.

National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

D. Podzamczer, B. Clotet, J. Miro, 2016 .

D. Podzamczer, J. Gatell, A. Rivero, 2015 .

osts and cost-efficacy analysis of the 2014 GESIDA/Spanish National IDS Plan recommended guidelines for initial antiretroviral therapy n HIV-infected adults

J. Gatell, A. Rivero, M. Tuset, 2014 .

Etiology of spontaneous pneumothorax in 105 HIV-infected patients without highly active antiretroviral therapy.

E. Cordero, J. Torre-Cisneros, Á. Camacho, 2009, European journal of radiology.

Usefulness of Sputum Culture for Diagnosis of Bacterial Pneumonia in HIV-Infected Patients

E. Cordero, J. Pachón, A. Rivero, 2002, European Journal of Clinical Microbiology and Infectious Diseases.

Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

D. Podzamczer, J. Mallolas, J. Caylà, 2016, Enfermedades infecciosas y microbiologia clinica.

Visceral leishmaniasis in HIV‐1 -infected individuals: a common opportunistic infection in Spain?

M. Leal, I. Velez, J. Pineda, 1992, AIDS.

Consensus document on the management of renal disease in HIV-infected patients.

E. Negredo, J. Miro, E. Martinez, 2014, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

Clinical differences between invasive pulmonary infection by Scedosporium apiospermum and invasive pulmonary aspergillosis

J. Torre-Cisneros, A. Rivero, M. J. Linares, 2011, Mycoses.

Hepatitis E virus infection in equines in Spain

A. Rivero, M. Risalde, I. García‐Bocanegra, 2018, Transboundary and emerging diseases.

Rural habitat as risk factor for hepatitis E virus seroconversion in HIV‐infected patients: A prospective longitudinal study

L. Real, J. Torre-Cisneros, F. Cuenca-López, 2017, Zoonoses and public health.

Familial Hepatitis E Outbreak Linked to Wild Boar Meat Consumption

D. Rodriguez-Cano, F. Cuenca-López, Á. Camacho, 2017, Zoonoses and public health.

Pre-transplant thymic function is associated with the risk of cytomegalovirus disease after solid organ transplantation.

M. Leal, R. Solana, J. Torre-Cisneros, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

R. Solana, J. Torre-Cisneros, A. Martín-Malo, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Comparative Quantitation of Cytomegalovirus (CMV) DNA in Solid Organ Transplant Recipients with CMV Infection by Using Two High-Throughput Automated Systems

Thomas F. Smith, T. F. Smith, W. Kremers, 2001, Journal of Clinical Microbiology.

Use of High-Dose Ganciclovir for the Treatment of Cytomegalovirus Replication in Solid Organ Transplant Patients With Ganciclovir Resistance-Inducing Mutations

E. Cordero, J. Torre-Cisneros, A. Rivero, 2013, Transplantation.

Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users.

L. Real, J. Macías, J. Pineda, 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Does lopinavir/ritonavir alter the primary gingival epithelium?

A. Rivero, I. Pérez-Camacho, 2010, Expert review of anti-infective therapy.

Protist enteroparasites in wild boar (Sus scrofa ferus) and black Iberian pig (Sus scrofa domesticus) in southern Spain: a protective effect on hepatitis E acquisition?

E. Dacal, J. Saugar, P. Köster, 2020, Parasites & Vectors.

Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

D. Podzamczer, J. Mallolas, J. Caylà, 2016, Enfermedades infecciosas y microbiologia clinica.

Hepatitis E Virus Infections in Free-Ranging and Captive Cetaceans, Spain, 2011–2022

R. Ulrich, A. Rivero, E. Martínez-Nevado, 2022, Emerging infectious diseases.

Diarrhoea-causing enteric protist species in intensively and extensively raised pigs (Sus scrofa domesticus) in Southern Spain. Part II: Association with Hepatitis E virus susceptibility.

P. Köster, D. Carmena, A. Rivero, 2021, Transboundary and emerging diseases.

Diarrhoea-causing enteric protist species in intensively and extensively raised pigs (Sus scrofa domesticus) in Southern Spain. Part I: Prevalence and genetic diversity.

P. Köster, D. Carmena, A. Rivero, 2021, Transboundary and emerging diseases.

Global molecular diversity of Hepatitis E virus in wild boar and domestic pig

A. Rivero, M. Risalde, I. García‐Bocanegra, 2021, One health.

Emergent subtype of hepatitis E virus genotype 3 in wild boar in Spain.

J. Vicente, J. Barasona, A. Rivero, 2019, Transboundary and emerging diseases.

Brucellosis in patients infected with the human immunodeficiency virus

D. Podzamczer, J. Miro, A. Rivero, 1998, European Journal of Clinical Microbiology and Infectious Diseases.

Hepatitis E Infection in HIV-Infected Patients

A. Rivero, P. López-López, A. Rivero-Juarez, 2019, Front. Microbiol..

Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain.

J. Pineda, A. Rivero, J. Portilla, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Stepped-Dose Versus Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events

A. Rivero, P. Viciana, F. Lozano, 2009, Annals of Internal Medicine.

Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.

C. Tural, V. Soriano, J. Macías, 2008, The Journal of antimicrobial chemotherapy.

Low Response to Pegylated Interferon plus Ribavirin in HIV-Infected Patients with Chronic Hepatitis C Treated with Abacavir

V. Soriano, J. Pineda, A. Rivero, 2008, Antiviral therapy.

Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.

J. Pineda, A. Rivero, L. López-Cortés, 2007, The Journal of antimicrobial chemotherapy.

Once-daily antiretroviral therapy: Spanish Consensus Statement.

D. Podzamczer, J. Mallolas, J. Ena, 2005, The Journal of antimicrobial chemotherapy.

[GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)].

J. Miro, M. Laguno, J. Vilardell, 2005, Enfermedades infecciosas y microbiologia clinica.

Efficacy of a comprehensive strategy for the detection and treatment of hepatitis C infection in a population attending addiction centers

Á. Camacho, A. Rivero, I. Pérez-Valero, 2023, Frontiers in Public Health.

Low Incidence of Severe Liver Events in HIV Patients With and Without Hepatitis C or B Coinfection Receiving Lopinavir/Ritonavir

J. Torre-Cisneros, J. Macías, J. Pineda, 2006, HIV clinical trials.

Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV

J. Gatell, A. Vibhagool, A. Lazzarin, 2004, Journal of acquired immune deficiency syndromes.

TUBERCULOSIS IN THE TRANSPLANT CANDIDATE: IMPORTANCE OF EARLY DIAGNOSIS AND TREATMENT

J. Torre-Cisneros, A. Rivero, J. M. Kindelán, 2004, Transplantation.

A case-control study of HIV patients with the K65R mutation in the reverse transcriptase gene with virological failure.

A. Rivero, M. Nogales, F. Lozano, 2005, AIDS.

Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.

J. Macías, J. Pineda, A. Rivero, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma

C. Tural, J. Pineda, A. Rivero, 2014, AIDS.

Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.

J. Macías, J. Pineda, Á. Camacho, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

High hepatitis E virus seroprevalence with absence of chronic infection in HIV-infected patients.

J. Torre-Cisneros, A. Gordon, J. Pineda, 2015, The Journal of infection.

Absence of occult Hepatitis E virus infection among HIV immunosuppressed patients.

J. Torre-Cisneros, A. Gordon, J. Pineda, 2015, The Journal of infection.

Incidence and natural history of hepatitis E virus coinfection among HIV-infected patients

L. Real, J. Macías, J. Pineda, 2014, AIDS.

High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease.

J. Macías, J. Pineda, Á. Camacho, 2015, Enfermedades infecciosas y microbiologia clinica.

Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy

B. Clotet, J. Arribas, A. Rivero, 2011, AIDS.

Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada).

A. Rivero, Jesús Santos, R. Palacios, 2007, The Journal of antimicrobial chemotherapy.

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.

M. Buti, R. Andrade, X. Forns, 2018, Gastroenterology.

Seroreversion of IgG anti‐HEV in HIV cirrhotic patients: A long‐term multi‐sampling longitudinal study

Á. Camacho, A. Rivero, M. Risalde, 2022, Transboundary and emerging diseases.

Hepatitis E 3ra Genotype Infection in People Living With HIV in Spain

J. Macías, A. Rivero, J. Berenguer, 2020, Frontiers in Microbiology.

Hepatitis E Virus (HEV) Infection in Anti-HEV Immunoglobulin G-Carrying Patients After Successful Hepatitis C Virus Treatment: Reactivation or Reinfection?

Á. Camacho, A. Rivero, I. Machuca, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV

J. Torre-Cisneros, J. Macías, J. Pineda, 2013, PloS one.

Human Immunodeficiency Virus Infected Patients are Not at Higher Risk for Hepatitis E Virus Infection: A Systematic Review and Meta-Analysis

Á. Camacho, A. Rivero, P. López-López, 2019, Microorganisms.

Role of Hepatitis E Virus Infection in Acute-on-Chronic Liver Failure

A. Rivero, P. López-López, A. Rivero-Juarez, 2018, BioMed research international.

Predictors of Severe Haematological Toxicity Secondary to Pegylated Interferon plus Ribavirin Treatment in HIV-HCV-Coinfected Patients

J. Macías, J. Pineda, A. Rivero, 2007, Antiviral therapy.

The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients

D. Meyer‐Olson, J. Rockstroh, M. Trauner, 2013, AIDS.

Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

J. Torre-Cisneros, J. Macías, J. Pineda, 2013, Infection.

Current views on interferon therapy for HIV

A. Rivero, A. Rivero-Juarez, M. Frías, 2016, Expert opinion on biological therapy.

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.

J. Navarro, J. Pérez-Molina, A. Rivero, 2015, The Lancet. Infectious diseases.

Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia

J. Macías, J. Pineda, A. Rivero, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients

J. Macías, J. Pineda, A. Rivero, 2012, AIDS.

Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy

J. Macías, J. Pineda, Á. Camacho, 2012, European Journal of Clinical Microbiology & Infectious Diseases.

Nevirapine-based antiretroviral therapy is associated with lower plasma hepatitis C virus viral load among HIV/hepatitis C virus-coinfected patients.

J. Pineda, A. Rivero, L. López-Cortés, 2010 .

Inﬂuence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients

J. Pineda, A. Rivero, L. López-Cortés, 2007 .

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

B. Clotet, M. Odriozola, J. Olalla, 2017, The Journal of antimicrobial chemotherapy.

Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study

A. Rivero, P. Viciana, L. López-Cortés, 2010, AIDS research and therapy.

Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection

M. Biasin, J. Soria, L. Real, 2015, Genes and Immunity.

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.

T. Larson, C. Payá, A. Rivero, 2001, The Journal of infectious diseases.

Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.

J. Torre-Cisneros, J. Macías, J. Pineda, 2004, The American journal of tropical medicine and hygiene.

Epidemiological survey and risk factors associated with hepatitis E virus in small ruminants in southern Spain

A. Rivero, M. Risalde, I. García‐Bocanegra, 2022, Zoonoses and public health.

Pain in the lower limbs of a patient with AIDS.

A. Rivero, J. M. Kindelán, M. García-Lázaro, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients.

M. L. de la Mata, G. Miño, M. Mata, 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Hepatitis E virus in the endangered Iberian lynx (Lynx pardinus)

R. Ulrich, A. Rivero, I. García‐Bocanegra, 2022, Transboundary and emerging diseases.

Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: first report in Europe.

J. Pineda, A. Rivero, J. C. Alados, 2022, Journal of hepatology.

Detection of Hepatitis E Virus in Hyalomma lusitanicum Ticks Feeding on Wild Boars

C. Gortázar, J. de la Fuente, J. Barasona, 2021, Frontiers in Microbiology.

Development and Clinical Validation of a Pangenotypic PCR-Based Assay for the Detection and Quantification of Hepatitis E Virus (Orthohepevirus A Genus)

Á. Camacho, A. Rivero, M. Risalde, 2020, Journal of Clinical Microbiology.

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

J. Benito, V. Soriano, J. McHutchison, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

First molecular characterization of the hepatitis E virus in humans in Cameroon: Confirmation of the HEV outbreak in Touboro, North‐Cameroon

M. Nola, R. Njouom, A. Rivero, 2020, Journal of medical virology.

Evaluation of a non-invasive screening approach to determine hepatitis E virus status of pig farms

Á. Camacho, A. Rivero, M. Risalde, 2020, Veterinary Record.

Survey for Hepatitis E virus infection in non-human primates in zoos in Spain.

A. Rivero, M. Risalde, I. García‐Bocanegra, 2019, Transboundary and emerging diseases.

The spatial pattern of human exposure to Crimean–Congo haemorrhagic fever virus is not consistent with red deer‐based risk predictions

F. Ruiz-Fons, A. Rivero, P. López-López, 2022, Transboundary and emerging diseases.

Age-Dependent Association between Low Frequency of CD27/CD28 Expression on pp65 CD8+ T Cells and Cytomegalovirus Replication after Transplantation

R. Solana, A. Rodríguez-Benot, J. Torre-Cisneros, 2009, Clinical and Vaccine Immunology.

A Genome-Wide Association Study on Liver Stiffness Changes during Hepatitis C Virus Infection Cure

A. Ruiz, I. de Rojas, L. Real, 2021, Diagnostics.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy].

B. Clotet, J. Gatell, J. Arribas, 2010, Enfermedades infecciosas y microbiologia clinica.

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).

D. Podzamczer, B. Clotet, J. Gatell, 2014, Enfermedades infecciosas y microbiologia clinica.

Prevalence and Risk Factors for Abnormal Liver Stiffness in HIV-infected Patients without Viral Hepatitis Coinfection: Role of Didanosine

J. Torre-Cisneros, J. Macías, J. Pineda, 2010, Antiviral therapy.

IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection

V. Soriano, L. Real, J. Macías, 2015, AIDS.

Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus‐coinfected patients with compensated liver cirrhosis

J. Macías, Á. Camacho, A. Rivero, 2012, Hepatology.

Kinetics of emergence of liver complications in HCV-infected patients and advanced fibrosis, with and without HIV-coinfection, after SVR.

L. Real, J. Macías, J. Pineda, 2021, AIDS.

Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions

E. Martinez, A. Rivero, S. Moreno, 2016, Open forum infectious diseases.

Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.

M. Crespo, J. Esteban, J. Pineda, 2008, The Journal of antimicrobial chemotherapy.

Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

D. Podzamczer, J. Mallolas, J. Losa, 2021, Trials.

Association of low-density lipoprotein receptor genotypes with hepatitis C viral load

L. Real, J. Pineda, Á. Camacho, 2013, Genes and Immunity.

Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy

Á. Camacho, A. Rivero, I. Machuca, 2017, PloS one.

Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.

B. Figueruela, J. Macías, J. Pineda, 2019, Journal of hepatology.

Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure

P. Soler-Palacín, Á. Holguín, J. Losa, 2021, The Journal of antimicrobial chemotherapy.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DU

D. Podzamczer, B. Clotet, E. Negredo, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Isolation of Hepatitis E Virus From Breast Milk During Acute Infection.

D. Rodriguez-Cano, F. Cuenca-López, A. Rivero, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence of hepatitis E virus infection in liver donors in Spain.

M. L. de la Mata, J. Torre-Cisneros, A. Rivero, 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Risk of tuberculosis after lung transplantation: the value of pretransplant chest computed tomography and the impact of mTOR inhibitors and azathioprine use

J. Torre-Cisneros, A. Rivero, J. Vaquero, 2016, Transplant infectious disease : an official journal of the Transplantation Society.

Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.

V. Soriano, J. Torre-Cisneros, J. Macías, 2014, The Journal of infection.

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients

J. Torre-Cisneros, J. Pineda, Á. Camacho, 2012, PloS one.

Is it time to start new HIV prevention strategies in Spain

A. Rivero, S. Moreno, 2017 .

Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort

J. Pineda, A. Rivero, M. Ríos, 2016, PloS one.

Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.

J. Macías, J. Pineda, A. Rivero, 2011, Journal of Antimicrobial Chemotherapy.

Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.

J. Macías, J. Pineda, A. Rivero, 2008, The Journal of antimicrobial chemotherapy.

Redefining therapeutic success in HIV patients: an expert view

J. Olalla, A. Rivero, S. Moreno, 2021, The Journal of antimicrobial chemotherapy.

[Safety profile of dolutegravir].

A. Rivero, P. Domingo, 2015, Enfermedades infecciosas y microbiologia clinica.

Transmission between HIV‐infected patients of multidrug‐resistant tuberculosis caused by Mycobacterium bovis

F. Baquero, D. van Soolingen, J. Blázquez, 1997, AIDS.

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis

A. Horban, S. Ouwerkerk-Mahadevan, J. Sasadeusz, 2014, Journal of the International AIDS Society.

Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals.

J. Macías, A. Rivero, Federico García, 2017, Diagnostic microbiology and infectious disease.

Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?

E. Ruiz-Mateos, J. Muñoz-Pichardo, A. Rivero, 2019, The Journal of antimicrobial chemotherapy.

Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria.

E. Cordero, J. Pachón, A. Rivero, 2000 .

Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.

A. Horban, S. Ouwerkerk-Mahadevan, J. Sasadeusz, 2016, The Journal of antimicrobial chemotherapy.

HAART induces the expression of HLA-G on peripheral monocytes in HIV-1 infected individuals.

J. Lozano, R. Solana, J. Torre-Cisneros, 2003, Human immunology.

[The Spanish AIDS Study Group and Spanish National AIDS Plan (GESIDA/Secretaría del Plan Nacional sobre el Sida) recommendations for the treatment of tuberculosis in HIV-infected individuals (Updated January 2013)].

J. Caylà, A. Rivero, S. Moreno, 2013, Enfermedades infecciosas y microbiologia clinica.

The future of antiretroviral therapy: challenges and needs.

E. Ribera, J. Arribas, A. Rivero, 2010, The Journal of antimicrobial chemotherapy.

Persistence of Pathological Distribution of NK Cells in HIV-Infected Patients with Prolonged Use of HAART and a Sustained Immune Response

J. Torre-Cisneros, F. Cuenca-López, A. Gordon, 2015, PloS one.

Rapid Improvement in Fasting Lipids and Hepatic Toxicity After Switching From Didanosine/Lamivudine to Tenofovir/Emtricitabine in Patients With Toxicity Attributable to Didanosine

A. Del Arco, A. Rivero, R. Palacios, 2010, HIV clinical trials.

Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR

J. Pineda, Á. Camacho, A. Rivero, 2019, Scientific Reports.

Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).

D. Podzamczer, B. Clotet, J. Gatell, 2015, Enfermedades Infecciosas y Microbiologia Clinica.

Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada®) in virologically suppressed HIV-infected patients on HAART

A. Rivero, F. Lozano, R. Palacios, 2009, European Journal of Clinical Microbiology & Infectious Diseases.

Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae.

J. Rodríguez-Baño, L. López-Cerero, Á. Pascual, 2015, The Journal of antimicrobial chemotherapy.

Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin.

A. Tenório, F. Pozo, J. Torre-Cisneros, 2000, AIDS (London).

Rapid Communications: Failure of a Short‐Term Prednisone Regimen to Prevent Nevirapine‐Associated Rash: A Double‐Blind Placebo‐Controlled Trial: The GESIDA 09/99 Study

J. Miro, J. Blanco, A. Rivero, 2001, Journal of acquired immune deficiency syndromes.

Prevalence of hepatitis E virus infection in wild boars from Spain: a possible seasonal pattern?

Á. Camacho, A. Rivero, M. Risalde, 2018, BMC Veterinary Research.

Monitoring of Hepatitis E Virus in Wild Lagomorphs in Spanish Mediterranean Ecosystems

A. Rivero, I. García‐Bocanegra, D. Cano‐Terriza, 2023, Transboundary and Emerging Diseases.

Temporal changes in the genotypes of Paslahepevirus balayani in southern Spain and their possible link with changes in pig trade imports

J. Pineda, A. Rivero, J. C. Alados, 2023, One health.

Risk factors associated with hepatitis E virus in pigs from different production systems.

Á. Camacho, A. Rivero, M. Risalde, 2018, Veterinary microbiology.

Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin

L. Real, J. Macías, J. Pineda, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection

V. Soriano, J. Macías, J. Pineda, 2013, European Journal of Clinical Microbiology & Infectious Diseases.

LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients

J. Torre-Cisneros, J. Pineda, Á. Camacho, 2012, AIDS.

Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy

J. Rockstroh, M. Trauner, C. Boesecke, 2014, Antiviral Therapy.

Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.

J. Torre-Cisneros, J. Pineda, A. Rivero, 2012, The Journal of antimicrobial chemotherapy.

Fat mass and obesity‐associated gene variations are related to fatty liver disease in HIV‐infected patients

J. Macías, A. Rivero, J. Gómez-Mateos, 2017, HIV medicine.

Optimization of the molecular diagnosis of the acute hepatitis E virus infection

J. Mesquita, A. Aguilera, J. Pineda, 2023, Microbial biotechnology.

J. Macías, J. Pineda, Á. Camacho, 2012, European Journal of Clinical Microbiology & Infectious Diseases.

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis

J. Macías, J. Pineda, Á. Camacho, 2015, BMC Infectious Diseases.

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial

J. De La Torre, J. Prada, S. Reus, 2018, The Journal of antimicrobial chemotherapy.

Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients

J. Rodríguez-Baño, J. Macías, J. Pineda, 2009, Gut.

[Decrease in the annual frequency of infectious endocarditis among intravenous drug users in southern Spain].

A. Rivero, A. de Alarcón, A. Vergara, 2000, Enfermedades Infecciosas y Microbiologia Clinica.

Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

D. Podzamczer, J. Gatell, A. Rivero, 2015, Enfermedades infecciosas y microbiologia clinica.

Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet

A. Rivero, F. Lozano, Jesús Santos, 2016, Journal of the International Association of Providers of AIDS Care.

HLA-B, HLA-C and KIR improve the predictive value of IFNL3 for Hepatitis C spontaneous clearance

D. Rodriguez-Cano, B. Manzanares-Martín, Á. Camacho, 2018, Scientific Reports.

Brief Report: Differential Timing of Cholesterol Increase During Successful HCV Therapy Impact of Type of Drug Combination

Á. Camacho, A. Rivero, M. Risalde, 2018, Journal of acquired immune deficiency syndromes.

A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.

J. Pineda, Á. Camacho, A. Rivero, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Monitoring of hepatitis E virus in zoo animals from Spain, 2007–2021

R. Ulrich, A. Rivero, E. Martínez-Nevado, 2022, Transboundary and emerging diseases.

Serological and molecular survey of hepatitis E virus in cats and dogs in Spain.

R. Ulrich, A. Rivero, E. Jurado-Tarifa, 2021, Transboundary and emerging diseases.

Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

A. Rivero, L. López-Cortés, M. Márquez, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

Presence of hepatitis E virus in testis of naturally infected wild boars

A. Rivero, M. Risalde, I. García‐Bocanegra, 2022, Transboundary and emerging diseases.

Detection of hepatitis E virus RNA in saliva for diagnosis of acute infection

Á. Camacho, A. Rivero, M. Risalde, 2018, Zoonoses and public health.

Post-mortem findings in Spanish patients with COVID-19; a special focus on superinfections

E. Álava, J. Miro, E. de Álava, 2023, Frontiers in medicine.

Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis

Mayda Martínez Rodríguez, R. Andrade, J. Pascasio, 2018 .

CD45RA expression on HCMV-specific effector memory CD8+ T cells is associated with the duration and intensity of HCMV replication after transplantation.

R. Solana, A. Rodríguez-Benot, J. Torre-Cisneros, 2010, Clinical immunology.

Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir.

J. Torre-Cisneros, J. Pineda, A. Rivero, 2006, The Journal of antimicrobial chemotherapy.

Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance

L. Real, A. Gordon, J. Pineda, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

Nucleoside reverse transcriptase inhibitors are able and protease inhibitors unable to induce the tolerogenic molecule HLA-G1 on monocytes from HIV-1 infected patients.

J. Lozano, Á. Camacho, J. Peña, 2007, Human immunology.

Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia

J. Macías, J. Pineda, A. Rivero, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients

J. Torre-Cisneros, A. Gordon, J. Pineda, 2014, PloS one.

Classification Accuracy of Hepatitis C Virus Infection Outcome: Data Mining Approach

J. M. Luna, H. Fardoun, Á. Camacho, 2020, Journal of medical Internet research.

Orthohepevirus C as causal agent of acute hepatitis in Spain.

A. Rivero, A. Rivero-Juarez, M. Frías, 2022, Revista Espanola de Enfermedades Digestivas.

C. Gortázar, D. Rodríguez-Lázaro, A. Avellón, 2020, Enfermedades infecciosas y microbiologia clinica (English ed.).

Limited Value of Single Sampling for IgM Antibody Determination as a Diagnostic Approach for Acute Hepatitis E Virus Infection

J. Pineda, A. Rivero, J. C. Alados, 2021, Microbiology spectrum.

Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.

J. Macías, J. Pineda, A. Rivero, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CD45RA expression on HCMV-specific effector memory CD8+ T cells is associated with the duration and intensity of HCMV replication after transplantation.

R. Solana, A. Rodríguez-Benot, J. Torre-Cisneros, 2010, Clinical immunology.

Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis

L. Real, J. Macías, J. Pineda, 2018, The Journal of antimicrobial chemotherapy.

Predictors of low‐level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

E. Poveda, A. Rivero, M. Rava, 2022, HIV medicine.

Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study.

Miguel Ángel Martínez, D. Podzamczer, C. Vidal, 2020, The Journal of antimicrobial chemotherapy.

Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals

L. Real, J. Macías, J. Pineda, 2015, AIDS.

Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

D. Podzamczer, J. Mallolas, J. Losa, 2021, Trials.

Differences in Virological Response to Peginterferon-&agr; Plus Ribavirin in HIV-Positive Patients Coinfected With HCV Subtypes 1a or 1b

J. Benito, V. Soriano, J. Pineda, 2012, Journal of acquired immune deficiency syndromes.

[Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients].

A. Rivero, F. Lozano, M. Márquez, 2007, Enfermedades infecciosas y microbiologia clinica.

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018).

D. Podzamczer, E. Negredo, J. Miro, 2019, Enfermedades infecciosas y microbiologia clinica.